The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a modified version of the Fresenius Biosol Powder Bicarbonate Concentrate. The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrate is substantially equivalent in chemical formulation, chemical composition, and intended use to the commercially available Biosol Powder Bicarbonate Concentrates currently distributed as Fresenius Naturalyte® Dry Pack Bicarbonate Concentrates.

AI/ML Overview

This document is a 510(k) Premarket Notification for a medical device called "Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special"". It is a submission to the FDA to demonstrate substantial equivalence to a predicate device.

Based on the provided text, a conventional acceptance criteria and study report of device performance in the typical sense (e.g., sensitivity, specificity, accuracy, etc., for a diagnostic device, or clinical outcome data for a therapeutic device) are not applicable because:

Device Type: This is a submission for a dialysate concentrate, which is a medical fluid used in hemodialysis. It is not a diagnostic imaging device, a treatment device with a measurable "performance" in terms of clinical outcomes presented in this document, or an AI-powered system.
Nature of the Submission: This is a 510(k) Premarket Notification, which aims to demonstrate that a new device is substantially equivalent to a legally marketed predicate device. This equivalence is typically proven by showing similar intended use, technological characteristics, and safety/effectiveness profiles, rather than through a detailed clinical efficacy trial with specific performance metrics and acceptance criteria in the way envisioned by the prompt's questions.
Content of the Document: The document focuses on comparing the modified device to its predicate in terms of chemical formulation, composition, and intended use. It explicitly states: "The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrates is a modified versions of the Biosol Powder Bicarbonate Concentrates. The technological characteristics of the modified devices are equivalent to those of the unmodified devices and raise no new types of safety or effectiveness questions."

Therefore, the prompt's questions regarding acceptance criteria, device performance, sample sizes for test/training sets, experts, adjudication methods, MRMC studies, standalone performance, and ground truth are not directly addressed or applicable to this type of regulatory submission for this specific device.

Instead, the "acceptance criteria" can be broadly interpreted as the FDA's criteria for determining "substantial equivalence," and "device performance" as successful demonstration of that equivalence.

Here's how to interpret the provided information given the context of a 510(k) submission for a dialysate concentrate:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria (for Substantial Equivalence via 510(k)):

Criteria	Reported "Device Performance" / How Met
Is the product a device? (21 CFR §201 [321] (h))	YES - "The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a device pursuant to 21 CFR §201 [321] (h)."
Does the new device have the same intended use as the predicate?	YES - "The intended use for the modified device is equivalent to the unmodified device." Both are "formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates."
Does the device have technological characteristics that raise new types of safety or effectiveness questions?	NO - "The technological characteristics of the modified devices are equivalent to those of the unmodified devices and raise no new types of safety or effectiveness questions." This implies chemical formulation and function are considered equivalent by the applicant.
Does descriptive or performance information demonstrate equivalence?	YES - "Fresenius Medical Care North America believes that the information provided in this submission clearly describes the modified Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate and demonstrates that it is substantially equivalent to the unmodified devices." The document states, "testing of the modified device indicates that the formulations are safe and effective for its intended use."
Safety and Effectiveness Concerns	The device is deemed "substantially equivalent in chemical formulation, chemical composition, and intended use to the commercially available Biosol Powder Bicarbonate Concentrates." General safety warnings are also provided (e.g., "Not for Parenteral Use").

2. Sample Size Used for the Test Set and Data Provenance

Not Applicable in the traditional sense. This submission does not report results from a clinical "test set" for performance metrics like sensitivity or specificity. Equivalence is primarily based on the chemical and functional characteristics compared to the predicate, and a statement about "testing of the modified device" which likely refers to bench testing or analytical chemistry, not human subject data in the way implied by the question.
Data Provenance: Not explicitly stated as human subject data. Chemical characteristic data would be from laboratory analysis.

3. Number of Experts and Qualifications for Ground Truth

Not Applicable. The "ground truth" here is the regulatory determination of substantial equivalence, based on the provided documentation and comparison to the predicate device, reviewed by FDA staff. It does not involve expert consensus on clinical findings in a dataset.

4. Adjudication Method for the Test Set

Not Applicable. No test set or adjudication process for human-interpreted data is described. The FDA performs regulatory review.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No. This is not an imaging device or an AI system that would typically involve an MRMC study to compare human readers with and without AI assistance.

6. Standalone (i.e., algorithm only without human-in-the-loop performance) Study

Not Applicable. This is a chemical concentrate, not an algorithm or AI system.

7. Type of Ground Truth Used

The "ground truth" for this 510(k) submission is the chemical formulation, composition, and intended use of the predicate device (Fresenius Biosol Powder Bicarbonate Concentrate K981043). The modified device is compared against these known characteristics to establish substantial equivalence. Implicitly, safety and effectiveness knowledge about the predicate device forms part of this "ground truth."

8. Sample Size for the Training Set

Not Applicable. There is no "training set" in the context of an AI/ML algorithm for this device.

9. How the Ground Truth for the Training Set was Established

Not Applicable. As there is no training set, this question is not relevant. The "ground truth" (predicate device's characteristics) was established through its prior regulatory clearance (K981043) and its documented chemical and functional properties.

Summary

{0}------------------------------------------------

K071387 Page 1 of 3

Image /page/0/Picture/1 description: The image shows a geometric design that resembles an inverted pyramid. The pyramid is constructed from a series of stacked, truncated inverted pyramids, each smaller than the one above it. The lines forming the shapes are thick and black, creating a bold contrast against the white background. The design is symmetrical and minimalist, with a focus on geometric precision.

JUN 1 5 2007

Fresenius Medical Care

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special" 510(k) Premarket Notification

510(k) Summary

A. Submitter's Information: Fresenius Medical Care North America Name: Address: 920 Winter Street Waltham, MA 02451 (781)699-4475 Phone: Fax: (781) 699-9635 Contact Person: Janet C. Kay, Manager Regulatory Affairs Date of Preparation: June 14, 2007

B. Device Name:

Trade Name:	Naturalyte® Sodium Bicarbonate LiquidConcentrate
Common/Usual Name:	Dialysate Concentrate for Hemodialysis (liquid)
Classification Name:	Hemodialysis systems and accessories

{1}------------------------------------------------

Ko71387 Page 2 of

Image /page/1/Picture/1 description: The image shows a geometric design that resembles a stylized, inverted pyramid or cone. The design is composed of four horizontal lines that create three distinct layers or sections within the overall shape. Each layer is defined by a pair of parallel lines, with the space between the lines filled in to create a solid, dark band. The layers decrease in size from top to bottom, giving the impression of depth or perspective.

Fresenius Medical Care

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special" 510(k) Premarket Notification

510(k) Summary

C. Predicate Device Name:

The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a modified version of the Fresenius Biosol Powder Bicarbonate Concentrate

#K981043 (5/26/1998) .

D. Device Description/Indications for Use:

The intended use for the modified device is equivalent to that of the unmodified device:

Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

E. Substantial Equivalence:

Substantial Equivalence Decision Making Process

1. Is the product a device?

YES - The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate is a device pursuant to 21 CFR §201 [321] (h).

2. Does the new device have the same intended use?

YES The intended use for the modified device is equivalent to the unmodified device.

Fresenius modified Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates - Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

Fresenius unmodified Biosol Powder Bicarbonate Concentrate -Intended Use

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

{2}------------------------------------------------

K07L387 Page 3 of 3

JUN 15 2007

Fresenius Medical Care

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate "Special" 510(k) Premarket Notification

510(k) Summary

3. Does the device have technological characteristics that raise new types of safety or effectiveness questions?

NO -- The Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates is a modified versions of the Biosol Powder Bicarbonate Concentrates. The technological characteristics of the modified devices are equivalent to those of the unmodified devices and raise no new types of safety or effectiveness questions.

4. Does descriptive or performance information demonstrate equivalence?

YES - Fresenius Medical Care North America believes that the information provided in this submission clearly describes the modified Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrate and demonstrates that it is substantially equivalent to the unmodified devices.

F. Safety Summary

The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrate is substantially equivalent in chemical formulation, chemical composition, and intended use to the commercially available Biosol Powder Bicarbonate Concentrates currently distributed as Fresenius Naturalyte® Dry Pack Bicarbonate Concentrates. In addition, testing of the modified device indicates that the formulations are safe and effective for its intended use.

G. General Safety and Effectiveness Concerns

The Fresenius modified Naturalyte® Sodium Bicarbonate Liquid Concentrates are to be used with a three-stream proportioning systems when calibrated to specified proportions depending on the series and mixed with water that meet ANSI/AAMI RD 62.. Use with other equipment or without associated bicarbonate concentrate may cause patient injury or death. Not for Parenteral Use.

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle head in profile, facing right, composed of three curved lines. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular fashion around the eagle head.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850

Ms. Janet C. Kay Manager of Regulatory Affairs Fresenius Medical Care North America 920 Winter Street WALTHAM MA 02451

JUN 15 2007

Re: K071387

Trade/Device Name: Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates, (4000 Series) Regulation Number: 21 CFR §876.5820 Regulation Name: Hemodialysis system and accessories Regulatory Class: II Product Code: KPO Dated: May 16, 2007 Received: May 18, 2007

Dear Ms. Kay:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Image /page/3/Picture/10 description: The image shows a circular logo with the text "FDA Centennial 1906-2006" in the center. The letters "FDA" are prominently displayed in a bold font. The word "Centennial" is written below the letters "FDA". The logo is surrounded by a ring of text and stars.

Protesting and Promoting Public Health

{4}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all. the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please eontact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx 21 CFR 884.xxxx 21 CFR 892.xxxxx Other

(Gastroenterology/Renal/Urology) 240-276-0115 (Obstetrics/Gynecology) 240-276-0115 (Radiology); 240-276-0120 240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html

http://www.fda.gov/oc/industry/support/index.html

Sincerely vours.

Nancy C. Brogdon

Nancy C. Brogdon Director, Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for Fresenius Medical Care. The logo consists of an inverted triangle shape with horizontal lines inside, above the text "Fresenius Medical Care". The text is in a simple, sans-serif font and is horizontally aligned.

Indications for Use

510(k) Number (if known):

Device Name:

Fresenius Naturalyte® Sodium Bicarbonate Liquid Concentrates, 4000 Series.

Indications for Use:

This concentrate is formulated to be used with a three steam hemodialysis machine which is calibrated for acid and bicarbonate concentrates

Prescription Use 4 (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off) Division of Reproductive, Abdomina and Radiological Device

510(k) Number K071387

(Posted November 13, 2003)

Page of

Fresenius Medical Care North America

Corporate Headquarters: 920 Winter Street Waltham, MA 02451 (781) 699-9000

Regulation Number and Section

§ 876.5820 Hemodialysis system and accessories.

(a)
Identification. A hemodialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and that consists of an extracorporeal blood system, a conventional dialyzer, a dialysate delivery system, and accessories. Blood from a patient flows through the tubing of the extracorporeal blood system and accessories to the blood compartment of the dialyzer, then returns through further tubing of the extracorporeal blood system to the patient. The dialyzer has two compartments that are separated by a semipermeable membrane. While the blood is in the blood compartment, undesirable substances in the blood pass through the semipermeable membrane into the dialysate in the dialysate compartment. The dialysate delivery system controls and monitors the dialysate circulating through the dialysate compartment of the dialyzer.(1) The extracorporeal blood system and accessories consists of tubing, pumps, pressure monitors, air foam or bubble detectors, and alarms to keep blood moving safely from the blood access device and accessories for hemodialysis (§ 876.5540) to the blood compartment of the dialyzer and back to the patient.
(2) The conventional dialyzer allows a transfer of water and solutes between the blood and the dialysate through the semipermeable membrane. The semipermeable membrane of the conventional dialyzer has a sufficiently low permeability to water that an ultrafiltration controller is not required to prevent excessive loss of water from the patient's blood. This conventional dialyzer does not include hemodialyzers with the disposable inserts (Kiil type) (§ 876.5830) or dialyzers of high permeability (§ 876.5860).
(3) The dialysate delivery system consists of mechanisms that monitor and control the temperature, conductivity, flow rate, and pressure of the dialysate and circulates dialysate through the dialysate compartment of the dialyzer. The dialysate delivery system includes the dialysate concentrate for hemodialysis (liquid or powder) and alarms to indicate abnormal dialysate conditions. This dialysate delivery system does not include the sorbent regenerated dialysate delivery system for hemodialysis (§ 876.5600), the dialysate delivery system of the peritoneal dialysis system and accessories (§ 876.5630), or the controlled dialysate delivery system of the high permeability hemodialysis system § 876.5860).
(4) Remote accessories to the hemodialysis system include the unpowered dialysis chair without a scale, the powered dialysis chair without a scale, the dialyzer holder set, dialysis tie gun and ties, and hemodialysis start/stop tray.
(b)
Classification. (1) Class II (performance standards) for hemodialysis systems and all accessories directly associated with the extracorporeal blood system and the dialysate delivery system.(2) Class I for other accessories of the hemodialysis system remote from the extracorporeal blood system and the dialysate delivery system, such as the unpowered dialysis chair, hemodialysis start/stop tray, dialyzer holder set, and dialysis tie gun and ties. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.